Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic performance of cervical cytology in HPV-independent cervical cancer: a comparative analysis with HPV-associated cases.

Journal of gynecologic oncology·2026
Same author

Overall survival with relacorilant and nab-paclitaxel in patients with platinum-resistant ovarian cancer (ROSELLA): a phase 3 randomised controlled trial.

Lancet (London, England)·2026
Same author

Survival implications of computed tomography-derived muscle mass changes in patients with epithelial ovarian cancer undergoing bowel surgery.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2026
Same author

Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial.

The Lancet. Oncology·2026
Same author

Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE).

Journal of gynecologic oncology·2026

Related Experiment Video

Updated: Jul 5, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Altered MicroRNA expression in cervical carcinomas.

Jeong-Won Lee1, Chel Hun Choi, Jung-Joo Choi

  • 1Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|May 3, 2008
PubMed
Summary

MicroRNA (miRNA) deregulation is implicated in cervical cancer progression. Targeting miR-199a suppressed tumor cell growth, suggesting potential prognostic and therapeutic strategies for cervical squamous cell carcinoma.

More Related Videos

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Related Experiment Videos

Last Updated: Jul 5, 2026

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization
06:01

Clinicopathological Analysis of miRNA Expression in Breast Cancer Tissues by Using miRNA In Situ Hybridization

Published on: June 7, 2016

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

Area of Science:

  • Molecular biology
  • Oncology
  • Genetics

Background:

  • MicroRNAs (miRNAs) are small noncoding RNAs regulating gene expression.
  • Emerging evidence links miRNA dysregulation to various human cancers.
  • Cervical squamous cell carcinoma (CSCC) pathogenesis may involve miRNAs.

Purpose of the Study:

  • To profile miRNA expression in early-stage invasive CSCC.
  • To investigate the role of overexpressed miR-199a in CSCC cell viability.
  • To identify potential miRNA biomarkers for CSCC prognosis and therapy.

Main Methods:

  • miRNA expression profiling using TaqMan real-time quantitative PCR array.
  • Analysis of miRNA expression in 10 ISCC and 10 normal cervical tissues.
  • In vitro functional studies involving transfection of cervical cancer cells with anti-miR-199a oligonucleotides.

Main Results:

  • Significant differential expression of 70 genes (68 upregulated, 2 downregulated) in ISCC compared to normal tissues.
  • Increased miR-127 expression correlated with lymph node metastasis in 31 ISCC patients (P = 0.006).
  • Anti-miR-199a transfection suppressed cervical cancer cell growth in vitro, enhanced by cisplatin.

Conclusions:

  • miRNA deregulation plays a significant role in cervical squamous cell malignant transformation.
  • Specific miRNAs, like miR-127 and miR-199a, are potential biomarkers for CSCC.
  • Targeting deregulated miRNAs offers novel prognostic and therapeutic strategies for cervical cancer.